TABLE 1.
Clinical and molecular features of diffuse large B‐cell lymphomas (DLBCL) cohorts
| Discovery dataset | DLBCL validation set (on trial) | DLBCL validation set (real‐world) | GSE117556 | |
|---|---|---|---|---|
| (N = 314) | (N = 175) | (N = 146) | (N = 893) | |
| IPI range | ||||
| High | 49 (15.6%) | 47 (26.9%) | 16 (11.0%) | 156 (17.5%) |
| High‐Int | 68 (21.7%) | 128 (73.1%) | 40 (27.4%) | 268 (30.0%) |
| Low | 121 (38.5%) | 0 (0%) | 51 (34.9%) | 244 (27.3%) |
| Low‐Int | 76 (24.2%) | 0 (0%) | 39 (26.7%) | 225 (25.2%) |
| COO | ||||
| ABC | 142 (45.2%) | 38 (21.7%) | 57 (39.0%) | 253 (28.3%) |
| GCB | 125 (39.8%) | 103 (58.9%) | 63 (43.2%) | 511 (57.2%) |
| UC | 47 (15.0%) | 34 (19.4%) | 25 (17.1%) | 129 (14.4%) |
| NR1H3 | ||||
| High | 266 (84.7%) | 154 (88.0%) | 122 (83.6%) | 837 (93.7%) |
| Low | 48 (15.3%) | 21 (12.0%) | 24 (16.4%) | 56 (6.3%) |
| Gender | ||||
| Female | 102 (32.5%) | 83 (47.4%) | 34 (23.3%) | 396 (44.3%) |
| Male | 149 (47.5%) | 92 (52.6%) | 40 (27.4%) | 497 (55.7%) |
| Age | ||||
| Median [Min, Max] | 62.0 [17.0, 92.0] | 52.0 [18.0, 65.0] | 64.2 [16.8, 87.7] | 64.7 [20.8, 86.1] |
Abbreviations: COO, cell of origin; IPI, international prognostic index.